IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer]. Rev Mal Respir. 2018 Sep 19;: Authors: Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M Abstract BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-small cell lung cancer (NSCLC). METHODS: This phase II study is designed to administrate three durvalumab IV infusions (10mg/kg at day 1, 15, 29) before surgery, to patients with pathologically confirmed NSCLC, clinical stage IB (>4cm) or stage II, ≥18 years of age, WHO performans status 0-1, without selection on PD-L1 expression. Preoperative chemotherapy and radiation therapy are not permitted. The primary objective is feasibility of complete surgical resection. Major pathological response on surgical tissue, defined as 10% or less remaining tumor cells, will be a secondary objective. Additional secondary objectives include tolerance, adverse effects, delay between start of treatment and surgery, response rate (RECIST 1.1)...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research

Related Links:

Publication date: Available online 9 October 2020Source: PhytomedicineAuthor(s): Jian-Shu Lou, Li-Ping Zhao, Zhi-Hui Huang, Xia-Yin Chen, Jing-Ting Xu, William Chi-Shing TAI, Karl W.K. Tsim, Yi-Tao Chen, Tian Xie
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Authors: Han AR, Lee S, Han S, Lee YJ, Kim JB, Seo EK, Jung CH Abstract Radiotherapy using ionizing radiation is a major therapeutic modality for advanced human lung cancers. However, ionizing radiation itself can induce malignant behaviors such as cancer cell migration and invasion, leading to local recurrence or distal metastasis. Therefore, safer and more effective agents that inhibit the metastatic behaviors of cancer cells in radiotherapy are needed. As a part of our ongoing search for new radiotherapy enhancers from medicinal herbs, we isolated the following triterpenoids from the ethanol extract of Centella ...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Publication date: Available online 8 October 2020Source: European Journal of RadiologyAuthor(s): Tao Yu
Source: European Journal of Radiology - Category: Radiology Source Type: research
Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): Jean-Baptiste Leclère, Ludovic Fournel, Harry Etienne, Charbel Al Zreibi, Ilaria Onorati, Arnaud Roussel, Yves Castier, Emmanuel Martinod, Françoise Le Pimpec-Barthes, Marco Alifano, Jalal Assouad, Pierre Mordant, thoracic surgery units of Paris Public Hospitals.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Condition:   Lung Cancer, Non-Small Cell Interventions:   Drug: Dostarlimab;   Drug: Pembrolizumab;   Drug: Chemotherapy Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: Aaptamine retarded the proliferation and invasion of NSCLC cells by selectively targeting the pathway PI3K/AKT/GSK3β suggesting it as a potential chemotherapeutic agent for repressing tumorigenesis and progression of NSCLC in humans. PMID: 33027592 [PubMed - in process]
Source: Pharmaceutical Biology - Category: Drugs & Pharmacology Tags: Pharm Biol Source Type: research
Conclusion: As far as we know, this study will be the first meta-analysis to compare the efficacy of the vein-first and artery-first surgical technique of segmentectomy for patients diagnosed with resectable non–small cell lung cancer. Due to the nature of the disease and intervention methods, RCTs may be inadequate, and we will carefully consider inclusion in high-quality, non-RCTs, but this may result in high heterogeneity and affect the reliability of the results. INPLASY registration number: INPLASY202080062
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
Rationale: Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer. Patient concerns: A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month. Diagnoses: Epidermal growth factor receptor (EGFR) wild-type advanced primary lung adenocarcinoma without brain or bone metastasis. Interventions: The patient failed 2 lines of pemetrexed/docetaxel plus carboplatin and third-line erlotinib. Fourth-line anlotinib was administered thereafter. Outcomes: The pulmonary lesions showed partial remission 5 months after anlotinib monotherapy. The patient dem...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
ConclusionIn proton-based 4D Robust SBRT, the interplay effects degraded the target dose distribution but were mitigated using iso-energy layer repainting techniques. However, there was no significant correlation between the number of repainting layers and improvements in the dose distributions. The optimal layer repainting times based on the interplay effect index were ascertained according to the patient characteristics.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Radiation Therapy | Respiratory Medicine | Study